文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

阿夫凯泰治疗梗阻性肥厚型心肌病的多域患者水平分析

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-11-18

24周时,阿夫凯泰在多个临床相关疗效指标上均优于美托洛尔,阳性或完全应答者比例分别为78%和3%(P<0.001)。

要点

  • 阿夫凯泰单药在改善运动能力和多项疾病负担指标上优于美托洛尔。
  • 阿夫凯泰组78%达到阳性或完全应答,美托洛尔组仅3%。
  • 阿夫凯泰各疗效指标的需治疗人数为1.5至5.0。

核心结论

  • 在有症状的梗阻性肥厚型心肌病患者中,阿夫凯泰单药治疗在多个临床相关疾病负担指标上优于美托洛尔单药治疗。

研究设计与样本

  • MAPLE-HCM试验的事后分析,患者随机接受阿夫凯泰(n=88)或美托洛尔(n=87),剂量根据生命体征和超声心动图滴定。

主要发现

  • 24周时,阿夫凯泰在所有疗效指标上均带来更大获益,需治疗人数为1.5至5.0。
  • 阿夫凯泰组阳性或完全应答者比例为78%,美托洛尔组为3%(P<0.001)。

关键数值与推荐

  • 临床应答基于五项指标:静息LVOT-G<30 mmHg且Valsalva<50 mmHg;NYHA分级改善≥1级和/或KCCQ-CSS改善≥10分;NT-proBNP降低≥50%;峰值耗氧量增加≥1.0 mL/kg/min;左房容积指数降低≥10%。
  • 应答分类:无应答(0项)、有限应答(1或2项)、阳性应答(3或4项)、完全应答(5项)。

临床怎么用

  • 阿夫凯泰可作为有症状梗阻性肥厚型心肌病的单药治疗选择,快速改善多项疾病负担指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation. The MAPLE-HCM trial showed greater improvement in exercise capacity and secondary endpoints for aficamten monotherapy vs metoprolol monotherapy. OBJECTIVES: The purpose of this study was to evaluate the effects of aficamten vs metoprolol across multiple clinically relevant and patient-centric measures of disease burden in oHCM. METHODS: Patients with oHCM and left ventricular outflow tract gradient (LVOT-G) ≥30 mm Hg at rest and/or ≥50 mm Hg with Valsalva were randomly assigned to aficamten (n = 88) or metoprolol (n = 87). Dose titration was based on vital signs and echocardiograms. Assessment of clinical response by treatment arm was based on improvement in multiple parameters reflecting oHCM disease burden: LVOT-G <30 mm Hg at rest and <50 mm Hg with Valsalva; ≥1 class improvement in NYHA functional class and/or ≥10-point improvement in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS); ≥50% reduction in N-terminal pro-B-type natriuretic peptide; ≥1.0 mL/kg/min increase in peak oxygen consumption (pVO2); and ≥10% reduction in left atrial volume index. Clinical response was classified by number of efficacy outcomes achieved: nonresponder (none), limited (1 or 2), positive (3 or 4), or complete (all 5). RESULTS: Baseline characteristics were similar for both treatment groups. For the overall cohort, mean age was 58 ± 13.2 years; 73 (42%) were women, 103 (70%) were in NYHA functional class II and 52 (30%) in class III, mean pVO2 was 19.9 ± 5.1 mL/kg/min, and mean KCCQ-CSS score was 66 ± 16. At 24 weeks, aficamten treatment was associated with greater benefits in all efficacy outcome measures, with numbers needed to treat ranging from 1.5 to 5.0 relative to metoprolol treatment. Patients treated with aficamten were more likely to be either positive or complete responders compared with patients treated with metoprolol (78% vs 3%, respectively; P < 0.001). CONCLUSIONS: In patients with symptomatic oHCM, aficamten monotherapy led to superior and rapid treatment benefits across several clinically relevant outcome measures of disease burden compared with metoprolol. These observations support the emerging role of aficamten as monotherapy for oHCM. (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM [MAPLE-HCM]; NCT05767346).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Wang A, Garcia-Pavia P, Masri A, et al. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. J Am Coll Cardiol. 2025. PMID: 41348072. doi:10.1016/j.jacc.2025.10.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。